Pregnancy, epilepsy, and anticonvulsants

Dialogues in Clinical Neuroscience

Volumn 10, Issue 1, 2008, Pages 63-75

  Steinhoff, Bernhard J ^a,b  

^a Epilepsy Center Kork   (Germany)

^b EPILEPSIEZENTRUM KORK   (Germany)

Author keywords

Antiepileptic drug; Delivery; Epilepsy; Fertility; Interaction; Pregnancy; Puerperium; Teratogenicity

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ESTROGEN; ETHINYLESTRADIOL; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; LICARBAZEPINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; VITAMIN K GROUP; ZONISAMIDE;

BLEEDING; DELIVERY; DISEASE DURATION; DRUG METABOLISM; DRUG MONITORING; ELECTROENCEPHALOGRAPHY; EPILEPSY; FERTILITY; HEALTH SURVEY; HORMONAL CONTRACEPTION; HUMAN; HYPERINSULINISM; LONG TERM CARE; MONOTHERAPY; OBESITY; PEDIATRICS; PERINATAL PERIOD; PREGNANCY; PUERPERIUM; REVIEW; RISK FACTOR; SIDE EFFECT; TERATOGENICITY; TESTOSTERONE BLOOD LEVEL;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; EPILEPSY; FEMALE; FERTILITY; FOLIC ACID; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT;

EID: 42149104443     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Morrell MJ, Giudice L, Flynn KL, et al. Predictors of ovulatory failure in women with epilepsy. Ann Neurol. 2002;52:696-697.
2. Penovich PE. The effect of epilepsy and its treatment on sexual and reproductive functions. Epilepsia. 2000;41:53-61.
3. Webber MP, Hauser WA, Ottmann R, Annegers JF. Fertility in persons with epilepsy: 1935-1974. Epilepsia. 1986;27:746-752.
4. Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia. 1980;21:261-271.
5. Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia. 1996;37:833-840.
6. Ndgegwa D, Rust J, Golombek S, Fenwick P. Sexual problems in epileptic women. Sex Mar Ther. 1986;1:175-177.
7. Bergen D, Daugherty S, Eckenfals E. Reduction of sexual activities in females taking antiepileptic drugs. Psychopathol. 1992;25:1-14.
8. Jensen P, Jensen SB, Sorensen PS. Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. Arch Sex Behav. 1990;19:1-14
9. Duncan S, Blacklaw J, Beastall GH, Brodie MJ. Sexual function in women with epilepsy. Epilepsia. 1997;38:1074-1091.
10. Tettenborn B, Genton P, Polson D. Epilepsy and women's issues: an update. Epileptic Disord. 2002;4:23-31.
11. Cogen PH, Antunes JL, Correll JW. Reproductive function in temporal lobe epilepsy: the effect of temporal lobectomy. Surg Neurol. 1979;12:243-246.
12. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol. 1986;43:347-350.
13. Bilo L, Meo L, Nappi C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia. 1988;29:612-619.
14. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunnen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1283-1388.
15. Morrell MJ, Springer E, Giudice L. Reproductive function in women with epilepsy on Inducing and noninducing antiepileptic drugs. Epilepsia. 1997;38:232.
16. Aull-Watschinger S. Fertilität und Schwangerschaft. In: Baumgartner, C, ed, Handbuch der Epilepsien. Vienna, Austria; New York, NY: Springer; 2001:971-977.
17. Bauer J. Störungen reproduktiver Funktionen durch Antiepileptika. Akt Neurol. 2002;29(suppl 1):S28-S29.
18. Cummings LN, Giudice L, Morrell MJ. Ovulatory function in epilepsy. Epilepsia. 1995;36:355-359.
19. Morrell MJ. Epilepsy in women: the science of why it is special. Neurology. 1999;53:42-48.
20. Fröscher, W. Sexualität, Fortpflanzung, Schwangerschaft. In: Fröscher, W, Vassella, F, Hufnagel, A, eds. Die Epilepsien. Grundlagen - Klinik - Behandlung. 2. Auflage. Stuttgart, Germany; New York, NY: Schattauer; 2004:263-280.
21. Herzog AG. A relationship between particular endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology. 1993;43:1907-1910.
22. Bauer J, Stoffel-Wagner B, Flügel D, Kluge M, Elger CE. The impact of epilepsy surgery on serum sex hormones and menstrual cycles in female patients. Seizure. 2000;9:389-393.
23. Stoffel-Wagner B, Bauer J, Flügel D, Brennemann W, Klingmüller D, Elger CE. Serum sex-hormones are altered in patients with chronic focal epilepsies treated with anticonvulsant drugs. Epilepsia. 1998;39:1164-1173.
24. Bauer J. Epilepsie, Schwangerschaft und Sexualität. Darmstadt, Germany: Steinkopff; 2005.
25. Schmitz I, Janzik HH, Mayer K. Persönlichkeitsstruktur und Sexualverhalten Anfallskranker unter Langzeitbehandlung mit DPH. Bibl Psychiatr. 1975;151:176-181.
26. Lühdorf K, Hareskov C, Lund M, Hansen JM, Christiansen P. A prospective study of the side-effects of antiepileptic drugs with special reference to excretion of androgens and cortisol. In: Penry JK, eds. Epilepsy: The VIIIth International Symposium, New York, NY: Raven Press; 1977:209-213.
27. London DR, Loizou LA, Butt WR, Rovei V, Bianchetti G, Morselli PL. The effect of anti-convulsant drugs (AED) on hormonal responses in normal volunteers. In: Johannessen SI, Morselli PL, Pippenger CE, Richens A, Schmidt D, Meinardi H, eds. Antiepileptic Therapy: Advances in Drug Monitoring, New York, NY: Raven Press; 1980:405-411.
28. Franceschi M, Perego L, Cavagnini F, et al. Effects of long-term antiepileptic therapy on the hypothalamic-pituitary axis in man. Epilepsia. 1984;25:46-52.
29. Isojärvi JIT. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia. 1990;31:438-445.
30. Murialdo G, Galimberti CA, Gianelli MV, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol. 1998;21:52-58.
31. Vainionpaa LK, Rattya J, Knip M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol. 1999;45:444-450.
32. Stephen LJ, Kwan P, Shapiro D, Dominiczak M, Brodie MJ. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia. 2001;42:1002-1006.
33. Steinhoff BJ. Nebenwirkungen der Antiepileptika. In: Fröscher, W Vassella, F Hufnagel A, eds. Die Epilepsien. Grundlagen - Klinik - Behandlung. 2. Auflage. Stuttgart, Germany; New York, NY: Schattauer; 2004:564-602.
34. Dinesen H, Gram L, Anderson T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70:65-69.
35. Ettinger A, Moshe S, Shinnar S. Edema associated with long-term valproate therapy. Epilepsia. 1990;32:211-213.
36. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172-177.
37. Bauer J. Gewichtszunahme und Endokrinopathie unter Valproinsä uretherapie. In: Krämer, G, Walden J. eds. Valproinsäure. Pharmakologie, klinischer Einsatz, Nebenwirkungen und Therapierichtlinien. 2. Auflage, Berlin, Germany; Heidelberg, Germany; New York, NY: Springer; 2002:342-358.
38. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiare F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol. 2002;17:265-268.
39. Luef G Abraham, I Hoppichler F, et al. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism. 2002;51:1274-1278.
40. Rattya J, Vainionpaa L, Knip M, Lanning P, Isojärvi JI. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics. 1999;103:588-593.
41. Isojärvi JIT, Rättyä J, Myllylä VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43:446-451.
42. Bauer J, Jarre E, Klingmüller D, Elger CE. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 2000;41:163-167.
43. Herzog AG, Seibel MM, Schomer D, Vaitukaitis J, Geschwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology. 1984;34:1389-1393.
44. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy. A review of the evidence. Drugs. 2003;63:1185-1227.
45. Isojärvi JL, Taubøll; E Herzog AG. Effect of antiepileptic drugs on reproductive function in individuals with epilepsy. CNS Drugs. 2005;19:207-223.
46. Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptives by women with epilepsy. JAMA. 1986;256:238-240.
47. Coulam CB, Annegers JF. Do antiepileptic drugs reduce the efficacy of oral contraceptives? Epilepsia. 1979;20:519-526.
48. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540-549.
49. Schmitz B, Steinhoff BJ. Epilepsien. Taschenatlas spezial. Stuttgart: Thieme; 2004.
50. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs. 2002;16:263-272.
51. Harden CL, Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology. 2006; 26(suppl 4):S56-S58.
52. Morrell MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia. 2003;44(suppl 4):S11-S20.
53. Fattore C, Cipolla G, Gatti G, et al. Induction ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783-787.
54. Krauss GL, Brandt J, Campbell M, Plat C, Summerfield M. Antiepileptic medication and oral contraceptive interactions: a national survey of neurologists and obstetricians. Neurology. 1996;46:1534-1539.
55. Zahn CA, Morrell MJ, Collins SD, Labiner DM, Yerby MS. Management issues for women with epilepsy: a review of the literature. Neurology. 1998;51:949-956.
56. Crawford P, Appleton R, Betts T, Duncan J, Guthrie E, Morrow J. The women with epilepsy guidelines development group. Best practice guidelines for the management of women with epilepsy. Seizure. 1999;8:201-217.
57. Betts T, Crawford P. Women and Epilepsy, London, UK: Martin Dunitz; 1998.
58. Zahn C. Neurologic care of pregnant women with epilepsy. Epilepsia. 1998;39(suppl 8):S26-S31.
59. Klein P, Herzog AG. Hormonal effects on epilepsy in women. Epilepsia. 1998;39(suppl 8):S9-S16.
60. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151-154.
61. Sabers A, Öhmann I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570-571.
62. Petrenaite V, Sabers A, Hansen-Schwartz J. Individual changes in lamotrigine plasma concentrations during pregnancy. Epilepsy Res. 2005;65:185-188.
63. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the coadministration of lamotrigine and a combined oral contraceptive in healthy female patients. Br J Clin Pharmacol. 2006;61:191-199.
64. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484-489.
65. Reimers A, Heide G, Brodtkorb E. Ethinyl estradiol, not progestereons, reduces lamotrigine serum concentration. Epilepsia. 2005;46:1414-1417.
66. Haukkamaa M. Contraception by Norplant subdermal capsules is not reliable in epileptic patients on anticonvulsant therapy. Contraception. 1986;33:559-565.
67. Odlind V, Ollsson SE. Enhanced metabolism of levonorgestrel during phenytoin treatment in a woman with Norplant implants. Contraception. 1986;33:257-261.
68. LaVaccare JA, Bergen D. Women with epilepsy. Clin Neuropharmacol. 2000;23:63-68.
69. Fröscher W, Herrmann R, Niesen M, Bülau P, Penin H, Hildenbrand G. The course of pregnancy and teratogenicity of antiepileptic drugs in 66 patients with epilepsy. Schweiz Arch Neurol Psychiatr. 1991;142:389-407.
70. Rémillard G, Dansky L, Andermann E, Andermann F. Seizure frequency during pregnancy and the puerperium. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D. eds. Epilepsy, Pregnancy and the Child, New York, NY: Raven Press; 1982:15-26.
71. Bassi V, Yerby MS, Devinsky O. Epilepsy. In: Hainline B, Devinsky O, eds. Neurological Complications of Pregnancy, 2nd ed. Philadelphia, Pa: Lippincott Williams & Williams; 2002:185-212.
72. Tomson T, Gram L, Sillanpää M, Johannessen SI, eds. Epilepsy snd Pregnancy, Petersfield, UK; Bristol, Pa: Wrightson Biomedical; 1997.
73. EURAP Study Group. Seizure control and treatment in pregnancy: observation from the EURAP epilepsy pregnancy registry. Neurology. 2006;66:354-360.
74. Nakken KO, Lillestølen KM, Taubøll E, Engelsen B, Brodtkorb E. Epilepsy and pregnancy - drug use, seizure control, and complications. Tidsskr Nor Laegeforen. 2006;126:2507-2510.
75. Bardy AH, Hiilesmaa VK, Teramo KA. Effect of pregnancy on the electroencephalogram of epileptic women. Acta Neurol Scand. 1988;78:22-27.
76. Barrett C, Richens A. Epilepsy and pregnancy: report of an epilepsy research foundation workshop. Epilepsy Res. 2003;52:147-187.
77. Endo S, Hagimoto H, Yamazawa H, et al. Statistics on deliveries of mothers with epilepsy at Yokohama City University Hospital. Epilepsia. 2004;45(suppl 8):S42-S47.
78. Bardy A. Epilepsy and Pregnancy, a Prospective Study of 154 Pregnancies in Epileptic Women [thesis]. Helsinki, Finland: University of Helsinki; 1982.
79. Hiilesmaa VK. Pregnancy and birth in women with epilepsy. Neurology. 1992:42(suppl 5):S8-S11.
80. Yerby MS, Friel PN, McCormick K. Antiepileptic drug disposition during pregnancy. Neurology. 1992;42:12-16.
81. Tennis P, Eldridge RR, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia. 2002;43:1161-1167.
82. Cunnington M, Tennis P, International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Lamotrigine and the risk of malformations in pregnancy. Neurology. 2005;64:955-960.
83. Tatum WO. Use of antiepileptic drugs in pregnancy. Expert Rev Neurother. 2006;6:1077-1086.
84. Tran TA, Leppik IE, Blesi K, Sathanandan ST, Remmel R. Lamotrigine clearance during pregnancy. Neurology. 2002;59:251-255.
85. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the Puerperium. Clin Pharmacokinet. 2007;46:209-219.
86. Christensen J, Sabers A, Sidenius P. Oxcarbazepine concentrations during pregnancy: a retrospective study in patients with epilepsy. Neurology. 2006;67:1497-1499.
87. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites durino pregnancy and Puerperium. Epilepsia. 2006;47:504-509.
88. Bjerkedal T, Bahna SL. The course and outcome of pregnancy in women with epilepsy. Acta Obstet Gynecol Scand. 1973;52:245-248.
89. Nelson KB, Ellenberg JH. Maternal seizure disorder, outcome of pregnancy, and neurologic abnormalities in the children. Neurology. 1982;32:1247-1254.
90. Yerby M, Koepsell T, Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia. 1985;26:631-635.
91. Kaplan PW, ed. Neurologic disease in women, New York, NY: Demos; 1998.
92. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology. 2000;55(suppl):S21- S31.
93. Leppik IE. Pregnancy and epilepsy. MINCEP Epilepsy Reports VIII, No. 6. 1999.
94. Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology. 1998;51:904-906.
95. Yerby MS. Contraception, pregnancy and lactation in women with epilepsy. Bailliere's Clin Neurol. 1996;5:887-908.
96. Schmitz B, Coban I, Kretz R, Gaus V, Eibach S. EURAP Deutschland Interim-Report 07/2007. Data on file.
97. Kaaja E, Kaaja R, Matila R, Hiilesmaa V. Enzyme-inducing antiepileptic drugs in pregnancy and the risk of bleeding in the neonate. Neurology. 2002;58:549-553.
98. Wallacee SJ. Prenatal and perinatal risk factors for epilepsy. In: Pedley TA, Medrum BS, eds. Recent Advances in Epilepsy 5, Edinburgh: Churchill Livingstone; 1992:91-106.
99. Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med. 1998;338:429-434.
100. Fröscher W. Antiepileptika-Therapie in der Schwangerschaft, Missbildungen, Wachstums- und Entwicklungsstörungen. In: Fröscher W, Vassella F, Hufnagel A, eds. Die Epilepsien. Grundlagen - Klinik - Behandlung. 2. Auflage. Stuttgart, Germany; New York, NY: Schattauer; 2004;657-667.
101. Rambeck B, Kuriemann G, Stodieck SR, May TW, Juergens U. Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol. 1997;51:481-484.
102. Liporace J, Kao A, D'Abreu. A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav. 2004;5:102-105.
103. Morrow J, Russell A, Guthrie E, et al. Malformation risk of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77:193-198.
104. Hägg S, Spigset O. Anticonvulsant use during lactation. Drug Saf. 2000;22:425-440.
105. Bar-Oz B, Nulman I, Koren G, lto S. Anticonvulsants and breast feeding: a critical review. Paediatr Drugs. 2000;2:113-126.
106. Crawford P. Epilepsy and pregnancy. Seizure. 2001;10:212-219.
107. Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet. 2002;39:251-259.
108. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132-1138.
109. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res. 1999;33:145-158.
110. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenes associated with maternal epilepsy. Epilepsia. 1997;38:381-390.
111. Bjerkedal T. Outcomes of pregnancy in women with epilepsy. Norway. 1967-1978. Congenital malformations. In: Janz D, Dam M, Richens A, Bossi L, Helge H, Schmidt D. eds. Epilepsy: Pregnancy and the Child, New York, NY: Raven Press; 1982, 289-295.
112. Robert E, Loefkvist E, Maugiére F, Robert JM. Evaluation of drug therapy and teratogenic risk in a Rhóne-Alpes district population of pregnant epileptic women. Eur Neurol. 1986;25:436-443.
113. Fröscher W. Teratogenic effects of antiepileptic drugs. Drugs Today. 1989;25:563-567.
114. Dolk, H McElhatton, P. Assessing epidemiological evidence for the teratogenic effects of anticonvulsant medication. J Med Genet. 2002,39:243-244.
115. Craig J, Russell A, Parsons L, et al. The UK epilepsy and pregnancy register: update of results. 1996-2002. Epilepsia. 2002;43:56.
116. Morrow JI, Russell A, Craig JJ, et al. Major malformations in the offspring of women with epilepsy: a comprehensive prospective study. Epilepsia. 2001;42:125.
117. Koch S, Göpfert-Geyer I, Jäger-Roman E, et al. Antiepileptika während der Schwangerschaft. Dtsch Med Wochenschr. 1983:108:250-257.
118. Shorvon S. Antiepileptic drug therapy during pregnancy: the neurologist's perspective. J Med Genet. 2002;39:248-250.
119. Hufnagel A. Epilepsien und ihre Therapie, Bremen, Germany; London, UK; Boston, Mass: Unimed; 2000.
120. Chang TY, Lai CW, Hu HY, Hsu JJ, Shih YH, Chen CP, Taiwanese Registry of Epilepsy and Pregnancy. Preliminary descriptive statistics of the Taiwanese Registry of Epilepsy and Pregnancy fort he first two years. Taiwan J Obstet Gynecol. 2007; 46:47-49.
121. Alsdorf R, Wyszynski DF. Teratogenicity of sodium valproate. Expert Opin Drug Saf. 2005;4:345-353.
122. Holmes LB. The teratogenicity of anticonvulsant drugs: a progress report. J Med Genet. 2002;39:245-247.
123. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med. 1989;320:1661-1666.
124. Niesen M, Fröscher W. Finger- and toenail hypoplasia after carbamazepine monotherapy in late pregnancy. Neuropediatrics. 1985;16:167-168.
125. Beyenburg S, Bauer J. Spezifische Aspekte der Beratung und Behandlung von Frauen mit Epilepsie. Nervenheilkunde. 2001;20:499-505.
126. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia. 2005; 46(suppl 9): S117-S124.
127. Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. 1982;2:937.
128. Lemire RJ. Neural tube defects. JAMA. 1988;259:558-562.
129. Oakeshott P, Hunt GM. Valproate and spina bifida. BMJ. 1989;298:1300-1301.
130. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia. 2004;45:1171-1175.
131. Samrén EB, van Duijn CM, Christiaens GC, Hofman A, Lindkout D. Antiepileptic regimens and major congenital abnormalities in the offspring. Ann Neurol. 1999;46:739-746.
132. Vajda FJ, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol. 2006;13:645-654.
133. Effer E, Krimmel L. Neue Aspekte in der gesetzlichen Mutterschaftsvorsorge. Dtsch Aerztebl. 1990;87:1937-1940.
134. Stahlmann R, Neubert D. Welche Medikamente sind erlaubt, welche sollte man meiden, welche sind kontraindiziert? Gynäkologe. 1987;20:129-136.
135. Cunnington M, Ferber S, Quartey G. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia. 2007;48:1207-1210.
136. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet. 1991;338:131-137.
137. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med. 1992;327:1832-1835.
138. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. N Engl J Med. 1999;341:1485-1490.
139. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia. 2001;42:750-753.
140. Hamster W, Petruch F. Schwangerschaft und Epilepsie. Die Auswikrungen von Antikonvulsiva und zerebralorganischen Anfällen auf die geistig-seelische Entwicklung der Kinder. In: Hallen O, Meyer-Wahl JG, Braun J. eds. Epilepsie 82, Reinbek: Einhorn; 1984, 248-253.
141. Vinten J, Adab N, Kini U, Gorry J, Gregg J, Baker GA; Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology. 2005;64:949-954.
142. Gaily E, Kntola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology. 2004;62:28-32.